Understanding the link between Aβ and tau pathology and mitochondrial dysfunction will allow the discovery of new drug targets for Alzheimer’s disease with the potential to develop causal drugs. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.